Delivery Order SPE2DB22D9207-SPE2DB24FH5ES

Award Date 8/26/24
Potential Completion Date 9/17/24
Potential Value $51K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $22,624.14, is for the delivery of Kadcyla 160 mg vials, a specialty oncology medication. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) with DMS Pharmaceutical Group Inc. under the DLA's SPE2DB program, which allows for the issuance...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler located in Park Ridge, Illinois. The $15,358.74 contract is for the delivery of Kadcyla 100 mg vials, a specialized oncology medication, by January 14, 2025. This order is placed under DMS Pharmaceutical Group's existing $499,999,999 Indefinite Delivery Contract (IDC) with the DLA, which enables the agency to issue...
The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract, valued at $92,166.76, to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. This contract is for the delivery of Kadcyla 160 mg vials and has an ultimate completion date of August 2, 2024. The contract is part of a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group Inc., valued up to $499,999,999, which allows the DLA to issue delivery orders for a...
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $39,982.26, was awarded by the Defense Logistics Agency (DLA) Medical Supply Chain division and has a period of performance through September 12, 2024. The contract is for the delivery of Kadcyla 160 mg vials, a specialty oncology medication. This delivery order is part of a larger indefinite delivery...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $51,195.60, is for the delivery of Kadcyla 100 mg vials, a specialty oncology medication. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999 and running through...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, worth $27,670.50, is a firm fixed-price delivery order for 100 mg vials of the oncology drug Kadcyla. The award is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program, which covers a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $18,853.45 contract is for the delivery of Kadcyla 160 mg vials, a specialty oncology medication. This order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. The IDC enables the DLA to issue...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $15,358.74, is for the supply of Kadcyla 100 mg vials, an oncology drug, with a period of performance through May 24, 2024. This order is issued under DMS Pharmaceutical Group's existing indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999,...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $12,798.90, is for the delivery of 100 mg vials of the drug Kadcyla. The delivery order is part of a larger indefinite delivery contract (IDC) with DLA, valued at up to $499,999,999, that allows the agency to issue orders for a comprehensive range of...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $15,915.24, is for the delivery of 100 mg vials of the cancer drug Kadcyla. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA, valued at $499,999,999 and valid through November 2026. The IDC...
  • SPE2DB22D9207
    Indefinite Delivery Contract
  • SPE2DB22D9207-SPE2DB24FH5ES
    Delivery Order

This firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $51,195.60, is for the supply of Kadcyla 100 mg vials, a specialty oncology medication. The award is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA under the SPE2DB program, valued at up to $499,999,999 and running through December 31, 2025. This IDC allows the DLA to issue delivery orders for a wide range of pharmaceutical products to support the medical supply needs of Department of Defense healthcare facilities worldwide. The contract has no set-aside designation.

Generated 11/25/24, 9:24 AM